The present invention relates generally to immunogenic combinations comprising at least five antigens of a Mycobacterium species as well as fusion thereof and nucleic acid molecules encoding such combined antigens and fusion. The present invention also relates to nucleic acid molecules, vectors, host cells and compositions comprising or encoding said combinations of mycobacterial antigens and fusion polypeptides as well as to methods for recombinantly producing them. The present invention also relates to methods of using said combinations of mycobacterial antigens, fusion polypeptides, vectors, host cells, compositions particularly for inducing or stimulating an immune response against a Mycobacterium infection or any disease caused by or associated with a Mycobacterium infection. The present invention also concerns antibodies directed to such mycobacterial antigens and fusion polypeptides that can be used in the diagnosis of a Mycobacterium infection and method of detection as well as kits of reagent comprising said combinations of mycobacterial antigens, fusion polypeptides, vectors, host cells, compositions or antibodies.

Provided herein, in some embodiments, are immunogenic compositions that include a cationic lipid nanoparticle (LNP) encapsulating messenger ribonucleic acid (mRNA) having an open reading frame encoding a viral, bacterial or parasitic antigen, a pan HLA DR-binding epitope (PADRE), and a 5 terminal cap modified to increase mRNA translation efficiency.

The invention is in the field of prevention or treatment of diseases, in particular infectious diseases, and more particularly in the field of multivalent vaccines. The inventors characterized 5 copy-back DI-RNAs produced by recombinant MV strains, including rMV-based vaccines and wild-type MV (wt-MV). The efficiency of these DI-RNAs productions in different cell types was compared. For the first time 5 copy-back DI-RNAs specific binding to RIG-I, MDA5 and LGP2 was assessed and linked to functional outcome in type-I IFN signalling. The inventors provide a composition of products comprising at least (i) a mixture of particles of a rescued recombinant MV-derived virus encoding at least one antigen (ii) a recombinant and/or purified protein, comprising at least one antigen. Regardless of the presentation of the products, and in particular regardless of whether the products are separated or readily separable or presented as a mixture.

Described herein are in vitro-transcribed (IVT) RNA molecules comprising, a 5 cap structure, a coding region encoding an antigen polypeptide, an immunostimulatory RNA sequence, and a poly(A) tail.

The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36 (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).

The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36 (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).

A nucleic acid-antigen peptide conjugate is described that is capable of forming a complex with polysaccharides that have a -1,3-glucan skeleton, such as schizophyllan, and which can efficiently present the antigen peptide in an antigen-presenting cell. A conjugate bonded, via a linker added to polydeoxyadenine and a disulfide bond, to an N-terminal cysteine residue of an antigen peptide that has eight or more amino acid residues having a cysteine residue at the N-terminal is capable of forming a complex with polysaccharides that have a -1,3-glucan skeleton, and can efficiently present the antigen peptide in an antigen-presenting cell.

The present invention provides a vaccine composition for use in neurodegenerative diseases and an infectious virus vaccine composition for inducing an antibody recognizing the conformation of antigens. The vaccine composition of the present invention induces the production of an antibody recognizing the conformation of antigens. The antibody recognizing the conformation of antigens has high specificity for an antigen, and thus can be useful for ameliorating, preventing or treating diseases.

Provided are methods and compositions for treating cancer in a subject in need thereof. One of the top gene products in glioblastoma multiforme (GBM) is KLRB1 (also known as CD161), a C-type lectin protein that binds to CLEC2D. Binding of CLEC2D to the KLRB1 receptor inhibits the cytotoxic function of NK cells as well as cytokine secretion. KLRB1 is only expressed by small subpopulations of human blood T cells, and consequently little is known about the function of this receptor in T cells. However, preliminary data demonstrate that KLRB1 expression is induced in T cells within the GBM microenvironment. In an exemplary embodiment, a method is provided comprising administering an agent capable of blocking the interaction of KLRB1 with its ligand. The agent may comprise an antibody or fragment thereof, which may bind KLRB1 or CLEC2D.

Disclosed by the present invention are a targeted CD73 antibody and an antibody-drug conjugate (ADC), and a preparation method therefor and application thereof. Further disclosed is a method for preparing the described monoclonal antibody and ADC. The monoclonal antibody and the corresponding ADC disclosed by the present invention can be efficiently and highly specifically combined with purified CD73 protein and CD73 on the surfaces of multiple tumor cells to block the catalytic activity of CD73 enzyme, and have high affinity, low immunogenicity and significant anti-tumor effect.